Dose Insider / Glossary / STEP 2

STEP 2Semaglutide for weight in people with type 2 diabetes

Updated November 20, 2026 · 3 min read · Davies et al., Lancet 2021; WEGOVY label

STEP 2 is the trial of semaglutide for weight in people with type 2 diabetes. It enrolled 1,210 adults with a body mass index of 27 or more and an HbA1c of 7% to 10%. They took semaglutide 2.4 mg, the Wegovy dose, semaglutide 1.0 mg, an Ozempic dose, or placebo, once a week for 68 weeks. Weight fell by 9.6% on 2.4 mg against 3.4% on placebo. It was published in The Lancet in 2021.1

67.4%Semaglutide 2.4 mg, 5% or more, share reaching each weight loss
Share reaching each weight lossSTEP 2, semaglutide 2.4 mg vs placebo, %SEMAGLUTIDE 2.4 MG5% or more67.4%10% or more44.5%15% or more25.1%PLACEBO5% or more30.2%15% or more4.3%Share reaching each weightlossSTEP 2, semaglutide 2.4 mg vs placebo, %SEMAGLUTIDE 2.4 MG5% or more67.4%10% or more44.5%15% or more25.1%PLACEBO5% or more30.2%15% or more4.3%

Label figures; average weight change −9.6% against −3.4%.

On this page

How the trial was run

Participants had been diagnosed with type 2 diabetes at least 180 days before screening and were recruited from 149 outpatient clinics in 12 countries. They were assigned in equal numbers to semaglutide 2.4 mg, semaglutide 1.0 mg or placebo, 404, 403 and 403 people, with a lifestyle program for all. The trial was double-blind and double-dummy, meaning each person injected volumes that hid which dose, if any, they received. Assignment was balanced by the diabetes medicines people already took and by their HbA1c, so that each group started from a similar point.1

The authors' conclusion was that semaglutide 2.4 mg once a week gave a superior and clinically meaningful decrease in body weight compared with placebo in adults with type 2 diabetes and excess weight.1

What it found

Davies et al., 2021.1

The Wegovy label reports the 2.4 mg and placebo groups of this trial with its own counting. From a start of about 100 kg, a loss of at least 5% was reached by 67.4% against 30.2%, and at least 10% by 44.5% against 10.2%. At least 15% was reached by 25.1% against 4.3%, and at least 20% by 12.8% against 2.3%.2

Why the loss is smaller with diabetes

The same dose lowered weight by 14.9% in STEP 1, in adults without diabetes, against 9.6% here.3 Tirzepatide shows the same pattern: on Zepbound 15 mg, adults without diabetes lost 20.9% and adults with type 2 diabetes 14.7% in its label trials.4 The trials do not set out to explain the gap. It is a consistent finding across the GLP-1 medicines, and it matters for expectations: someone with type 2 diabetes comparing their progress with the headline numbers from trials in people without diabetes will usually fall short of them.

2.4 mg against 1.0 mg

STEP 2 tested the Wegovy and Ozempic doses side by side in the same kind of people. The summary we read reports the weight result of 2.4 mg against placebo; for the 1.0 mg group it reports side effects. Stomach and gut events were somewhat more common on 2.4 mg, 63.5% against 57.5% on 1.0 mg.1 The two brands differ in approved use as well as in dose: Ozempic treats type 2 diabetes and Wegovy is approved for weight. Our page on Ozempic and Wegovy sets the two labels side by side, including what each costs and which conditions each is approved for.

Limits

The trial was funded by Novo Nordisk. Its participants had an HbA1c of 7% to 10%, so it says little about people with very high blood sugar or people on insulin-heavy regimens, and it did not test Ozempic's top dose of 2 mg.1

Sources

  1. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971-984. Funded by Novo Nordisk; NCT03552757. doi:10.1016/S0140-6736(21)00213-0
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
  4. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov

Related analyses

Log your weight and HbA1c and see both trends on one screen.

Open Dose Insider